<SEC-DOCUMENT>0001213900-25-039694.txt : 20250505
<SEC-HEADER>0001213900-25-039694.hdr.sgml : 20250505
<ACCEPTANCE-DATETIME>20250505161526
ACCESSION NUMBER:		0001213900-25-039694
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250502
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250505
DATE AS OF CHANGE:		20250505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aditxt, Inc.
		CENTRAL INDEX KEY:			0001726711
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				823204328
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39336
		FILM NUMBER:		25913153

	BUSINESS ADDRESS:	
		STREET 1:		737 N. FIFTH STREET, SUITE 200
		CITY:			RICHMOND
		STATE:			VA
		ZIP:			23219
		BUSINESS PHONE:		909-488-0844

	MAIL ADDRESS:	
		STREET 1:		737 N. FIFTH STREET, SUITE 200
		CITY:			RICHMOND
		STATE:			VA
		ZIP:			23219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aditx Therapeutics, Inc.
		DATE OF NAME CHANGE:	20201113

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADiTx Therapeutics, Inc.
		DATE OF NAME CHANGE:	20171229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0240881-8k_aditxt.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ADTX="http://aditxt.com/20250502">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_ADTX_aditxt.com_20250502 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20250502_20250502 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001726711 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000004" name="dei:EntityCentralIndexKey">0001726711</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="adtx-20250502.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-05-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-02</xbrli:startDate>
        <xbrli:endDate>2025-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20250502__20250502_zZBnNcYMIs3g"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Pursuant to Section 13 OR 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_90E_edei--DocumentPeriodEndDate_c20250502__20250502_znVgUoxT2QCf"><ix:nonNumeric contextRef="AsOf2025-05-02" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May 2, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20250502__20250502_zQtAvTLoi8I8"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000011" name="dei:EntityRegistrantName">Aditxt, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20250502__20250502_zjztFE68MHUe"><ix:nonNumeric contextRef="AsOf2025-05-02" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityFileNumber_c20250502__20250502_zJavXmWl2EO"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000013" name="dei:EntityFileNumber">001-39336</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20250502__20250502_zHdie6T7YjN6"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000014" name="dei:EntityTaxIdentificationNumber">82-3204328</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250502__20250502_zCfGpFznlXgh"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000015" name="dei:EntityAddressAddressLine1">2569 Wyandotte Street</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20250502__20250502_zBiYMqgcCKHl"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 101</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20250502__20250502_zYVVxCsOtGwi"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000017" name="dei:EntityAddressCityOrTown">Mountain View</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20250502__20250502_zqQtnbrE59Kd"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000018" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric> </span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20250502__20250502_zkMXycNphMEd"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000019" name="dei:EntityAddressPostalZipCode">94043</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_90E_edei--CityAreaCode_c20250502__20250502_zpDWexIjhWxl"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000020" name="dei:CityAreaCode">650</ix:nonNumeric></span>) <span id="xdx_906_edei--LocalPhoneNumber_c20250502__20250502_zYCyVw8iAG41"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000021" name="dei:LocalPhoneNumber">870-1200</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--WrittenCommunications_c20250502__20250502_zZk9tBRxbCK6"><ix:nonNumeric contextRef="AsOf2025-05-02" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425 )</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SolicitingMaterial_c20250502__20250502_zfc6RjV4A9z"><ix:nonNumeric contextRef="AsOf2025-05-02" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20250502__20250502_z81AiRMuwiJi"><ix:nonNumeric contextRef="AsOf2025-05-02" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20250502__20250502_zkySYEy4ESl6"><ix:nonNumeric contextRef="AsOf2025-05-02" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20250502__20250502_zWk30zvS0wU1"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.001</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20250502__20250502_z4tS5KZQ1bw9"><ix:nonNumeric contextRef="AsOf2025-05-02" id="Fact000027" name="dei:TradingSymbol">ADTX</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_905_edei--SecurityExchangeName_c20250502__20250502_zWY6sVBytZ3g"><ix:nonNumeric contextRef="AsOf2025-05-02" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <span id="xdx_905_edei--EntityEmergingGrowthCompany_c20250502__20250502_zKwFJhOl16Tc"><ix:nonNumeric contextRef="AsOf2025-05-02" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_90B_edei--EntityExTransitionPeriod_c20250502__20250502_ziZbYkbwSDBk"><ix:nonNumeric contextRef="AsOf2025-05-02" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b></b></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white"><b>Item
7.01 Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2025, Aditxt, Inc. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;)
hosted a weekly update featuring Amro Albanna, the Chief Executive Officer of the Company, Shahrokh Shabahang, the Chief Innovation Officer
of the Company, and Dr. Friedrich Kapp, the Co-Chief Executive Officer of the Company&#8217;s subsidiary, Adiumune, Inc. (&#8220;<span style="text-decoration: underline">Adimune</span>&#8221;),
which highlighted recent developments related to ADI-100<sup>TM</sup>, the lead therapeutic candidate of Adimune. A copy of the transcript
of the weekly update is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in this item, including
that incorporated by reference, is being furnished to the Securities and Exchange Commission. Such information shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information
shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of
1933, except as expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Cautionary Note on Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">This
Current Report on Form 8-K contains certain forward-looking statements within the meaning of the &#8220;safe harbor &#8220;provisions
under the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained
in this&#160;</span>Current Report on Form 8-K<span style="background-color: white">, including statements regarding the Company&#8217;s
future results of operations and financial position are forward-looking statements. These forward-looking statements generally are identified
by the words &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221;
&#8220;intend,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;opportunity,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221;
&#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;will be,&#8221; &#8220;will continue,&#8221; &#8220;will likely
result,&#8221; and similar expressions.&#160;</span>These statements are based on various assumptions, whether or not identified in this
Current Report on Form 8-K, and on the current expectations of the management team of the Company and are not predictions of actual performance.
These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied
on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances
are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">These
forward-looking statements are subject to a number of risks including, but not limited to, the following risks: (1) the risk that the
Company&#8217;s currently proposed transactions may not be completed in a timely manner or at all, which may adversely affect the price
of the Company&#8217;s securities; (2) the failure to satisfy the conditions to the closing of the transactions, including the approval
by the stockholders of the acquisition target; (3) the ability to realize the anticipated benefits of the proposed transactions;</span>&#160;and
(4) other risks and uncertainties indicated from time to time in the Company&#8217;s public filings with the SEC. If any of these risks
materialize or the Company&#8217;s assumptions prove incorrect, actual results could differ materially from the results implied by these
forward-looking statements. You should carefully consider the risks and uncertainties described in the &#8220;Risk Factors&#8221; section
of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and other documents we filed, or will file, including the
proxy statement/prospectus, with the SEC. There may be additional risks that the Company does not presently know, or that the Company
currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements.
In addition, forward-looking statements reflect the Company&#8217;s expectations, plans or forecasts of future events and views as of
the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments will cause the Company&#8217;s
assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaim any obligation to do so, except as otherwise required by law. These forward-looking statements should not
be relied upon as representing the Company&#8217;s assessments of any date subsequent to the date of this Current Report on Form 8-K.
Accordingly, undue reliance should not be placed upon the forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Disclaimer:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information contained in the transcript furnished as Exhibit 99.1
is a textual representation of an audio recording of the weekly update and while efforts are made to provide an accurate transcription,
there may be material errors, omissions or inaccuracies in the reporting of the substance of the audio recording. The Company does not
assume any responsibility for any investment or other decisions made based upon the information provided in this transcript. Users are
advised to review the audio recording and the Company&#8217;s SEC filings before making any investment or other decisions. An archived
recording of the weekly update will be available for 30 days on the &#8220;Investor Relations&#8221; section of the Company&#8217;s website
at www.aditxt.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea024088101ex99-1_aditxt.htm">Transcript of Weekly Update&#8211; May 2, 2025</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: May 5, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aditxt, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="width: 35%; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Amro Albanna</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amro Albanna</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwkAMRU/QO4RZS50WddGdFhWxihQRt4NNZbCdlMxY2yN5S8cWMXwIyf8vEWIitrTRFTJcV3kGZ6ybSjmEHEtkNDf0iXS3T8D3HO/aOlbGDeMPTMkz6JlFKG9+PyRbbbFIQM6nXvEcIpnEM1geRPD1UzKlLtA4rSpQpoATU8ManeJ+vHBWHRmq++HTBdlqMglEoRztN8QyiuFIrXoRPyxkWSqCyVCB2DI9G59adw7Nl4R1hbV/Z0f6r+ADwQ5KSg== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea024088101ex99-1_aditxt.htm
<DESCRIPTION>TRANSCRIPT OF WEEKLY UPDATE - MAY 2, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (00:05):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All right. Welcome everybody. I do see people are starting to join,
so I&rsquo;m just going to take a few seconds to make sure that everybody gets the beginning of the Aditxt weekly updates. I see some people
joining right now, and with that we probably can get started. Maybe a couple more people here, a couple more seconds. So, hello everybody.
Good morning, good afternoon, good evening. My name is Amro Albanna. I am the Co-Founder and CEO of Aditxt. We have these weekly updates
for our stakeholders, our team members, our partners and our shareholders to make sure that we keep everybody engaged and updated on the
status of our business. So with that, I wanted to make sure we discuss the data that we announced a few weeks ago for the ADI-100, which
is a product of Adimune. And with that, I wanted to invite Shahrokh, our Chief Innovation Officer and Co-Founder, and Friedrich, who is
the Co-CEO of Adimune to discuss the data. But before we get into it, maybe Shahrokh, why don&rsquo;t you get us started by introducing yourself?</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (01:20):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I&rsquo;ll say good day to cover all time zones, and thank you for joining
us. I&rsquo;m Shahrokh Shabahang, Chief Innovation Officer of Aditxt, and my role is to support all innovations as they pertain to product development
and launch.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (01:35):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wonderful. Thank you, Shahrokh. And Friedrich, you&rsquo;ve been with us
before and why don&rsquo;t you just do a quick intro and we&rsquo;ll get started from there.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (01:45):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yeah, thank you and good day to all watching and listening. I&rsquo;m Friedrich
Kapp and I&rsquo;m responsible at Adimune for the development of ADI-100 and moving it to the clinical development phase and the clinical trials.
And I&rsquo;m very excited about it and will share with you why.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (02:06):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wonderful. So that said, just like the last couple of times folks that
are joining us, please, we do welcome Q&amp;A. You see the Q&amp;A button at the bottom of the screen. We truly, truly welcome the questions
and answers and that goes for our team members as well. This is, again, a public forum. Given the various programs that we are working
on, given the fact that we are all operating from different locations, this is a great forum for all of us, whether you&rsquo;re a team member,
partner, or any other type of stakeholders, it is a good forum for you to ask questions. So here it is. I will be monitoring the Q&amp;A
and certainly we welcome your questions and we&rsquo;ll provide some answers. So that way maybe Shahrokh, today we&rsquo;re going to be focusing on
Adimune. It is our first subsidiary.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(02:57):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The focus is on autoimmunity and addressing autoimmunity as one of
the most pressing health challenges. And with that, why don&rsquo;t you just give us an overview of what autoimmunity is. That, of course inclusive
of multiple sclerosis, type 1 diabetes, psoriasis, and the various other types of autoimmunity diseases that we deal with.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (03:20):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you, Amro. And autoimmune diseases really can be summarized in
one statement, and that is that our own immune system, which is really designed to protect us against potentially harmful external stimuli
or forces to start attacking aberrantly our own tissues. And why that happens, there are a lot of different schools of thought, and maybe
it&rsquo;s one, maybe it&rsquo;s a combination of things that lead to that and what the etiology is hard to pinpoint. But the fact remains that something
starts that process and the body starts to recognize our own tissues as foreign as something that could be dangerous and needs to attack.
And some of those components of those tissues are shared. So it may know a particular protein, for instance, which is the target of the
autoimmune attack, can be in one particular tissue like the heart, or it can be in multiple tissues, in which case you might have several
different organs or tissues engaged in that process. But that&rsquo;s in a nutshell what we&rsquo;re looking at with autoimmunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (04:44):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">And autoimmunity can develop at any age randomly as far as its initial
stage?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (04:52):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It can. And there&rsquo;s, of course, been a lot of work done on the genetic
predispositions to certain types of autoimmune diseases. And we know that there are certain individuals that carry certain genes that
render them more susceptible. But at the end of the day, it&rsquo;s not just your genes that you&rsquo;re born with, it&rsquo;s also the environmental factors
that can have an impact on your system in general that can later on in life lead to autoimmune issues.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (05:25):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Generally speaking, Shahrokh, what has been the method and approach
to addressing autoimmunity, generally speaking?</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (05:31):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Generally speaking, it&rsquo;s really, again simple, it&rsquo;s suppression of
the immune system. So you basically try to down-regulate the whole immune response as a whole in order to not have as much impact or autoimmune
response to what disease indication you&rsquo;re trying to address. And of course the side effect with that is that because the immune system
is being down-regulated, sort of blanketly, then you&rsquo;re leaving the body susceptible to other harmful stimuli and other harmful diseases
like infectious diseases and cancers.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (06:13):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So the good news is you&rsquo;re slowing the pace of rejection or at least
the pace of attacking our own tissues but obviously the challenge here is you&rsquo;re also opening up our system to be susceptible to other
diseases that our immune system would handle.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (06:29):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yeah, essentially you&rsquo;re disabling the ability of the immune system
to do what it was designed to do.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (06:36):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So Friedrich, that&rsquo;s it. And given the mission of Aditxt and our business
model, which I will continue to repeat, where we identify a promising innovation or a promising business, we&rsquo;ll bring it in-house, build
it, we support it for the purpose of positioning it for global commercialization. So Adimune as a company has a platform, ADI and ADI-100
is the first product candidate based on the ADI platform. Why don&rsquo;t you maybe share with us what is fundamentally different than existing
approaches to addressing autoimmunity?</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (07:12):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yeah, thank you, Amro. I think there must be a much better approach
than to suppress the immune system. And the better approach would be to restore immune tolerance. Because immune tolerance is disrupted
in autoimmune disease. You need to restore it. And when you think about how to do that and how to approach this task, then it&rsquo;s a good
idea to look at how does the body itself maintain tolerance. And the point is that the system, the immune system responds to dying cells.
And the dying cell can either be a danger signal or it can be just normal turnover, just of these many hundreds of millions of cells that
are being turned off-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART 1 OF 4 ENDS [00:08:04]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (08:03):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Just of these many hundreds of million cells that are being turned
over every day. And in that second case, the immune system says, &ldquo;Well, let&rsquo;s tolerate.&rdquo; So the immune system can either attack
a dying cell because it&rsquo;s dangerous or it can really down-regulate or keep the immune system down-regulated or regulate and maintain tolerance
that way. So if you take this into account, then you have two observations because the immune system always identifies and detects antigens.
And so there is the dying cell, which we call an apoptotic cell, and there is an antigen. And when that is detected, then you can really
maintain tolerance or use this system, apoptosis and antigen presentation, to restore tolerance. And that&rsquo;s the principle of ADI-100.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(09:12):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So we have, of these two components of our drug, there&rsquo;s one that induces
a small amount of dying cells. And the other component of our drug presents an antigen. It&rsquo;s actually in our case, GAD, G-A-D. It&rsquo;s an
antigen related. We&rsquo;ve used an antigen related to the one that, for example, in type one diabetes is the one that causes the disease when
being attacked by the immune system as part of the autoimmune disease that&rsquo;s evolving in type one diabetes. So the dying cell, the antigen
presentation, and then the down regulation of the attacking part with our ADI-100 to restore immune tolerance.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (10:03):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So Friedrich, basically our immune system, there is a natural mechanism,
a [inaudible 00:10:10] mechanism, which is tolerance, that tolerates our own tissues and cells. It wouldn&rsquo;t make any sense for our immune
system to attack our own cells, right? We want to make sure the immune system obviously addresses external threats, all threats, right?
So our own mechanism of tolerance, somehow the immune system forgets that one of our antigens or tissues or organs, that it&rsquo;s ours and
it will begin to attack it. And what we&rsquo;re trying to do with ADI is to retrain it or to remind it that this is ours, recognize it as our
itself and therefore do not attack it. So we&rsquo;re really trying to replace the suppression with restoring the natural order to remind it
that it&rsquo;s our own tissue. Is that fair enough? Is that correct?</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (11:05):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That&rsquo;s very well and correctly described. And our drug ADI-100 uses
a related antigen to the one that is being attacked. And that is important because if you use the one that&rsquo;s being attacked, it doesn&rsquo;t
make much sense. With the related antigen, we have shown in many experiments that we can really, with this principle of inducing apoptosis
and presenting this modified antigen downregulate the autoaggression against self.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (11:40):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Great. And I do see we have a question from Mike. Mike, I&rsquo;ll get back
to you here in a second to answer your question, which relates to cancer. So that said, Shahrokh obviously autoimmunity. Kind of back
to the Aditxt model. Our model is our DNA, no pun intended, is to truly identify these promising innovations, promising companies, where
we believe they have the potential of addressing major health challenge. And with autoimmunity, can you shed some light? Can you quantify
that challenge? Because there are about 80 to a hundred different autoimmune diseases, right? I started with type one diabetes and psoriasis
and multiple sclerosis. I think our participants and future audience will begin to understand how big autoimmunity is. But can you at
least maybe provide some examples of other areas? Because obviously there are some DERN related, there is autoimmune, there is CNS type.
So if you can shed some light, maybe that would be helpful for everybody listening in.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (12:49):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sure. I mean, as you said, autoimmunity is a big issue. So, 80 to a
hundred or so have been identified. There&rsquo;s probably going to be more identified or reclassification of the existing diseases that we
know of. There&rsquo;s approximately 50 million people in this country, in the US alone, affected by one form of autoimmunity or another, which
really dwarfs number of people that are impacted by cancer and heart disease put together. So it is a major problem. And essentially you&rsquo;re
dealing with really, when you compare autoimmunity with cancer, you&rsquo;re dealing with two sides of the same coin. In one case, you have
a overreactive immune response to our own tissues. In the other case, in the case of cancer, you have inability of the immune system to
recognize the cancer cells, but it all has to be preferably a specific response in these cases. So what we are doing here is with a ADI
platform as a whole, we are developing a tolerance delivery system that can be expanded to other indications.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(14:05):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Now we&rsquo;ve selected a particular antigen. Initially it was selected
because it&rsquo;s one of the culprits in type one diabetes. It happens that it was a good antigen to select overall, because now we know more
and more that glutamic acid decarboxylase, which is an enzyme, very important enzyme in the body, is found in many, many tissues. So ADI-100
can have applications to several indications, even though it&rsquo;s still antigen specific. In other words, it&rsquo;s not downregulating the immune
response to everything. It&rsquo;s to that particular antigen, it happens that that antigen is found in many tissues including skin, including
again the pancreas and many, many neural systems.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(14:59):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So there are perhaps 200 or more GAD-mediated central nervous system
autoimmune diseases. So again, with the ADI technology, our focus right now is on this particular antigen. But the idea is that, as Friedrich
alluded to, we can potentially switch out the current antigen with other targets to do the same thing, to induce tolerance to that specific
antigen. In the case of cancer, it is again different. And one important thing here that we have shown is that currently there are therapeutics
that, they&rsquo;re called checkpoint inhibitors, that essentially up-regulate the overall response to cancer, but then they can cause some
autoimmune issues. And we have shown in our studies that we can actually, in a targeted way-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART 2 OF 4 ENDS [00:16:04]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (16:02):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">... is that we can actually in a targeted way, reduce the autoimmune
component without touching the ability of those drugs to address the therapeutic effect on cancer.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (16:19):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Great. So I&rsquo;m going to go ahead and read Mike&rsquo;s question. And Mike
again, thanks for asking a question here. So I will just summarize it. Mike is mentioning something about a company that was featured
on CBS News and his question is, &ldquo;Does your research possibly help towards fighting cancer as well? And if so, could it work for
all types of cancer or is it only geared towards certain types?&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(16:45):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So let me maybe begin and then I&rsquo;ll turn it over to you, Friedrich.
One, so we do have a subsidiary that&rsquo;s working on early detection of cancer using mitochondrial DNA. That&rsquo;s Pearsanta. And I do see Chris
joining the call. I&rsquo;m sure Chris would love to join in and really talk about cancer detection because as we understand, the higher probability
comes from early detection of cancer. So that is Pearsanta, which we&rsquo;re working towards initially with prostate cancer, endometriosis
followed by ovarian cancer and other types of cancer. So early detection and eventually and potentially prevention through Adductomics,
but that is still an R&amp;D stage.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(17:28):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Now, back to Adimune when it comes to cancer and Friedrich again, maybe
you can shed some light. When we&rsquo;re talking about autoimmunity, even out of the ADI context, when we&rsquo;re talking about autoimmunity, it
sounds like with immunosuppressants in general, we&rsquo;re down regulating the immune system. That&rsquo;s our goal to make sure that, again, we
slow the pace of rejection of our own tissues. But the issue is, when you down regulate an immune system, you want to make sure that the
immune system is highly alert to fight cancer. That seems to be the dilemma as I heard it from Shahrokh.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(18:06):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So through tolerance and through ADI, and of course we got to remind
everybody, we are still preclinical. There is still work to be done, there is still approvals to be obtained. We are still at a preclinical
stage and Shahrokh and Friedrich will discuss that. But in general, Friedrich with ADI approach, when it comes to tolerance, how do you
characterize the fact that tolerance, the mechanism we use with tolerance, the goal here is not to interfere with fighting cancer because
you&rsquo;re not down regulating the immune system?</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (18:39):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yeah, I understood Michael&rsquo;s question in a way, if our drug would also
be suitable for fighting cancer. I will have to explain briefly that that is not the case and it&rsquo;s also not the intention. And we are
actually very happy, as Shahrokh mentioned, that we do not interfere with a drug like the checkpoint inhibitor drugs that are fighting
cancer, but also inducing autoimmune disease, that we take care of the autoimmunity part without interfering with the anti-cancer part
of the checkpoint inhibitor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(19:14):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That does not say that this particular technology that we have would
not be suited in the future to be modified in a way that instead of inducing or restoring immune tolerance, now being modified to selectively
and adjutant specifically attack on tumors. But the constructs that we do have, the two components are generated and designed in several
ways that I didn&rsquo;t address and don&rsquo;t want to go into details to really make sure that we only restore autoimmunity without the risk of
achieving the opposite.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(20:01):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That was one concern of several investigators that we spoke with. And
we have now very good data from human tissue, in vitro or ex vivo as we call it, to show that everything we have seen in mice when we
looked for restoring autoimmune tolerance can also be achieved with cells taken from patients that have anti-GAD autoimmunity. And that
is a fantastic finding, which is very exciting because it&rsquo;s so promising for our work. And we can go into some details with that.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (20:40):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Great. So obviously this is pretty significant science and Shahrokh,
I want you to just maybe touch on the patents that are protecting ADI and then we&rsquo;ll go to Friedrich and we&rsquo;ll discuss now the status
where we are. And ultimately, ultimately our goal is to make sure that we get it to humans. That&rsquo;s ultimately the goal, which is a journey.
So I want to talk about the status, what we&rsquo;re looking at next. But before we go there, maybe Shahrokh quickly, you can describe the IP
portfolio that we currently have for ADI.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (21:14):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sure. We have a pretty extensive IP portfolio for ADI and related technologies
using in-body induction of, again, this apoptosis or programmed cell death, which is a physiologic cell death, not a cell death that causes
inflammation. Over probably somewhere between 130, 150 patents and patent applications that are related to this technology. The patent
strategy initially starts by finding patents for things that you find, but really as the technology becomes more mature, you start taking
a much more comprehensive look at strategizing, how to capture what you&rsquo;re trying to do, not just now but in the future.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(22:12):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">And that&rsquo;s one of the key things that we have done in the most recent
years in again forming a patent portfolio around the whole apoptotic DNA immunotherapy or ADI technology, which is again, as I mentioned,
a tolerance delivery system, which can be used for delivering tolerization for any antigen. So that&rsquo;s really the objective. And even though
we have specific patents, for instance, or ADIC-100 with respect to type 1 diabetes and some of the other indications that involve GAD,
specifically, the whole ADI platform has also been protected.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (23:00):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Great. Friedrich, just in case people missed it, obviously with your
background, how many drugs have you been responsible for bringing to commercialization in your previous chapter?</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (23:13):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I call it a couple.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (23:15):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All right, well you&rsquo;re very humble. You&rsquo;re very humble. And you&rsquo;re
based in Berlin, Germany.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (23:21):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yeah.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (23:22):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So let&rsquo;s talk about the journey of bringing this drug, at least to
begin human trials. That&rsquo;s a big milestone in any drug development cycle. So maybe where we are or what we&rsquo;ve been up to, where we are
and what do you see as the next step?</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (23:42):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yeah, well, thank you very much. We have essentially completed, essentially
we&rsquo;ve completed everything that&rsquo;s needed. We have been in touch with our health authority in Germany because two of the clinical studies
we are planning will be done in Germany. They&rsquo;re very supportive and we will study psoriasis and type 1 diabetes and we will-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART 3 OF 4 ENDS [00:24:04]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (24:03):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">...study psoriasis and type 1 diabetes and we will study stiff-person
syndrome and other neurological diseases in the United States. All of them having a guide component. We did all the element experiments,
we did toxicology, we did the bio-distribution and persistence, antibody formation against the drug. All positive data. Really not a single
one that&rsquo;s raising a flag, so we are very happy.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(24:36):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">And as I mentioned just before, these new findings was achieved with
ex-vivo from patient-derived material is really very promising because the anti-GAD activity, immune activity was down-regulated with
our drug. And that is wonderful because you see the type 1 diabetes, let&rsquo;s talk about this for a minute. It&rsquo;s a special type of autoimmunity
because it&rsquo;s not treated with immunosuppressants, it&rsquo;s treated with insulin. Now it&rsquo;s caused by immune activity against GAD. And not only
do you see that in patients that have already been diagnosed with type 1 diabetes, but in normal people, normal individuals that are at
risk of developing type 1 diabetes.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(25:40):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So that is where you see also the anti-GAD immunity. And so everyone
is looking, in the field is looking for a drug that down-regulates that autoimmunity against GAD because then you go into prevention.
Patients that you treat with ADI-100, there&rsquo;s the promise and my expectation that they will never develop the disease. Early diagnosed
diabetes patients, type 1 diabetes patients will be treated and will essentially be okay from time-to-time, maybe six to 12 months later
they may have to get another injection with our drug. We have observed in mouse models for 300 days and then stopped the experiment. So
now let&rsquo;s do a little mess with the audience.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(26:43):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you take away the cause of the disease, eliminate the immunity against
GAD. If you eliminate the cause of the disease, what happens to the disease? Well, it is also going down. Now when the disease is not
there, what happens to insulin? Is also not needed anymore. Only perhaps in risk situations, as a rescue therapy. So I don&rsquo;t want to promise
too much, I&rsquo;m just talking about my personal expectations based on these data. And it&rsquo;s so fascinating that we can prevent and then treat
early disease. The one thing that we have to find out is what happens to the disease that&rsquo;s already established for several years or many
years? Is there something left that can be revitalized? Are there stem cells that have not been destroyed like the beta cells and can
they be revitalized and build new beta cells? And therefore that&rsquo;s what we need to find out.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(27:54):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">And also, in psoriasis when we treat, my expectation is that the disease
is also going to go down and be eliminated. We have to see for how long and when do we need to retreat. But it&rsquo;s very promising. And so
the point is that we either heal or stop the disease and avoid progression from the date of first diagnosis. And that is very important
for patients that suffer from stiff person syndrome because the progression is really devastating. And if you hope that you have made
a very good contribution to the health of these patients, and that&rsquo;s-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (28:48):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your enthusiasm is very contagious, Friedrich. And I can tell you truly,
all of our stakeholders, starting with myself, we could not have a better partner and a better leader to lead Adimune and ADI. And that&rsquo;s
why we&rsquo;re here. And now that we only have a minute left, I would say the same thing about Shahrokh. Our team members and partners are
behind the scene, and this forum is so important for the world to see the people behind the achievements and the accomplishments that
we have been been making. And ADI, certainly Adimune could not be possible without Shahrokh and his team. And we just simply don&rsquo;t have
enough time or days to even address that. So with that, maybe Shahrokh, any final words you would like to share before I conclude this
session?</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (29:45):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Just two things. I want to echo what you said. There&rsquo;s a tremendous
amount of teamwork behind the scenes to conduct all of these experiments that need to be done, writing reports and getting things ready
for our submissions for regulatory agencies. And I have to thank all of our team members who&rsquo;ve been truly engaged in this process. And
the last thing I&rsquo;ll mention is that when you are bringing a new drug into the clinic, the first thing that you want to make sure as much
as possible is to make sure it&rsquo;s safe. And we&rsquo;ve really done a lot of studies to not only ensure that the drug doesn&rsquo;t have toxicity,
but also to look and see if it can... What kind of an impact it could have on the response and reactivity to GAD. And that&rsquo;s one of the
things that has been done. And finally to select really the patients who would best benefit from this. So we&rsquo;ve done a lot of work in
that area and we&rsquo;re looking forward to seeing how this performs and we&rsquo;re feeling pretty comfortable with going into the clinic with it
at this stage.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (31:02):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wonderful. Thank you, Shahrokh. Thank you again for joining. Friedrich,
thank you again very much.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (31:06):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amro Albanna (31:07):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">And thanks to all of you for joining us and hopefully we see all of
you again next week.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shahrokh Shabahang (31:12):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Friedrich Kapp (31:12):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you. Bye-bye. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART 4 OF 4 ENDS [00:31:15]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 8</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>adtx-20250502.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 86o5s7xRiXhun8uDb31cWa2OGaPty5BxuZkxsmx/HUmKTyAh60VLyCYui+gmwTkJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ADTX="http://aditxt.com/20250502" elementFormDefault="qualified" targetNamespace="http://aditxt.com/20250502">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aditxt.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20250502_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20250502_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>adtx-20250502_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>adtx-20250502_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aditxt.com/role/Cover" xlink:href="adtx-20250502.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aditxt.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 02, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  02,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aditxt, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001726711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3204328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2569 Wyandotte Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mountain View<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">870-1200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .R!I5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .R!I5H\C"Z<[0   "L"   1
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M> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( .V!I5J7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ [8&E6JK$(A8S 0
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M6N=6RKV'5[+E&''\GN4/4$L#!!0    ( .V!I5HD'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #M@:5:99!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ [(&E6CR,+ISM    *P(  !$
M ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ [(&E6IE<G",0
M!@  G"<  !,              ( !WP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #L@:5:\6/;C8($  "^$0  &               @($@"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ [8&E6I^@&_"Q
M @  X@P   T              ( !V P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " #M@:5:EXJ[',     3 @  "P              @ &T#P  7W)E;',O
M+G)E;'-02P$"% ,4    " #M@:5:JL0B%C,!   B @  #P
M@ &=$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ [8&E6B0>FZ*M
M^ $  !H              ( !_1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ [8&E6F60>9(9 0  SP,  !,              ( !
MXA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  +!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0240881-8k_aditxt.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aditxt.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adtx-20250502.xsd</File>
    <File>adtx-20250502_lab.xml</File>
    <File>adtx-20250502_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0240881-8k_aditxt.htm">ea0240881-8k_aditxt.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0240881-8k_aditxt.htm": {
   "nsprefix": "ADTX",
   "nsuri": "http://aditxt.com/20250502",
   "dts": {
    "schema": {
     "local": [
      "adtx-20250502.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "adtx-20250502_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adtx-20250502_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0240881-8k_aditxt.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://aditxt.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0240881-8k_aditxt.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0240881-8k_aditxt.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aditxt.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-25-039694-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-039694-xbrl.zip
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MI-+Y <2P:<>C% 4(1]-9'QI2[1.,JR2-,"V\7,EM:4?S+%K7@(!V34A:PJ!
M@=R!L!0!FID\Q"LP_R)8#,.EIO0#2\NJ'95*%B HIK<^3)3>"R2SK1 -U_",
M TN=W93M,5O=GP5T08#28ZYUU[:0-T#Q- -=LBS)]NIQNIOM9D6$I7%MB2LV
M('.:";,\"!8 4R8#A0PI'2J$7GI>WR5@F7J($6R.*7-+@-UDDX*F)B 2K,8
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M8Z@(TT7GR->-W>#>35M\XWZY]Z_:+?\#4$L#!!0    ( .V!I5I2=W\<JAD
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M5R%*NW^,=E^S_\0.6^.&M0M7@$1REUJ$S9@1^/P:2QK@N9EW8\1R3^%[8H2
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M5A'R4.DO?48G2Q&R' 4A10  ,WUX7/8&A0Y0*9B0+AUCN\RM@H]C175"C$6
MK('RYA"F+P(3VTK.G=CGS@2TI9["<0+=PR!"H*:8&4>&G%A3M*\96B#5F%P&
M%&NDC&%/26M!9?Q%8[@AN:E:PN 2J%B(,9)F#%L #D,5ZLSS:!N1$O+N)F4S
M#"X@"%&WC'MXGH>8'%,0$!OLS2> IL=QTPK@H^>6':6885O@^T@XD[A$Y"'O
M0Y;</)L2+#9W;%,Q'P1:.!8&.C'&/FFL\M-Z[%N+4^4]<JJ(O8LPZ-!UCWS
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MJ)/)PC69ZQM\Z+U=N9(:H46!*YVEYBM;S<*5-8U%3?_BM_!#*YIY?6C/_-&
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M.DX*<:.*?='7<R-^">#F +*!5I#9#T7;,3CJK5G!D!\Q9X_(=-VA='Q^?7$
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M-CX^%BM,#^C,-N'X;C@=0 '.X4V\V_T8U3(!(*HT"^MSRL=VKIH!+"VCJ/&
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M,#(U,#4P,BYX<V102P$"% ,4    " #M@:5:7KB=Z?T*  !_A@  %0
M        @ %8 P  861T>"TR,#(U,#4P,E]L86(N>&UL4$L! A0#%     @
M[8&E6BZR,I%6!P  T%<  !4              ( !B X  &%D='@M,C R-3 U
M,#)?<')E+GAM;%!+ 0(4 Q0    ( .V!I5I2=W\<JAD  -2&   7
M      "  1$6  !E83 R-# X.#$M.&M?861I='AT+FAT;5!+ 0(4 Q0    (
M .V!I5I/)O/#&RD  !NX   <              "  ? O  !E83 R-# X.#$P
H,65X.3DM,5]A9&ET>'0N:'1M4$L%!@     %  4 5 $  $59      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ea0240881-8k_aditxt_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adtx-20250502.xsd" xlink:type="simple"/>
    <context id="AsOf2025-05-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2025-05-02</startDate>
            <endDate>2025-05-02</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-05-02" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-05-02" id="Fact000004">0001726711</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-05-02" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-05-02" id="Fact000010">2025-05-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-05-02" id="Fact000011">Aditxt, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-05-02" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-05-02" id="Fact000013">001-39336</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-05-02" id="Fact000014">82-3204328</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-05-02" id="Fact000015">2569 Wyandotte Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-05-02" id="Fact000016">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-05-02" id="Fact000017">Mountain View</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-05-02" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-05-02" id="Fact000019">94043</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-05-02" id="Fact000020">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-05-02" id="Fact000021">870-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-05-02" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-05-02" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-05-02" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-05-02" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-05-02" id="Fact000026">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-05-02" id="Fact000027">ADTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-05-02" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-05-02" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-05-02" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
